Compelling genetic evidence links the amyloid precursor protein (APP) to Alzheimer's disease (AD). A leading hypothesis proposes that a small amphipathic fragment of APP, the amyloid β-protein (Aβ), self-associates to form soluble assemblies loosely referred to as "oligomers" and that these are primary mediators of synaptic dysfunction. As such, Aβ, and specifically Aβ oligomers, are targets for disease modifying therapies. Currently, the most advanced experimental treatment for AD relies on the use of anti-Aβ antibodies. In this study, we tested the ability of the monomer-preferring antibody, m266 and a novel aggregate-preferring antibody, 1C22, to attenuate spatial reference memory impairments in J20 mice. Chronic treatment with m266 resulted in a~70-fold increase in Aβ detected in the bloodstream, and a~50% increase in water-soluble brain Aβ -and in both cases Aβ was bound to m266. In contrast, 1C22 increased the levels of free Aβ in the bloodstream, and bound to amyloid deposits in J20 brain. However, neither 1C22 nor m266 attenuated the cognitive deficits evident in 12 month old J20 mice. Moreover, both antibodies failed to alter the levels of soluble Aβ oligomers in J20 brain. These results suggest that Aβ oligomers may mediate the behavioral deficits seen in J20 mice and highlight the need for the development of aggregate-preferring antibodies that can reach the brain in sufficient levels to neutralize bioactive Aβ oligomers. Aside from the lack of positive effect of m266 and 1C22 on cognition, a substantial number of deaths occurred in m266-and 1C22-immunized J20 mice. These fatalities were specific to anti-Aβ antibodies and to the J20 mouse line since treatment of wild type or PDAPP mice with these antibodies did not cause any deaths. These and other recent results indicate that J20 mice are particularly susceptible to targeting of the APP/Aβ/tau axis. Notwithstanding the specificity of fatalities for J20 mice, it is worrying that the murine precursor (m266) of a lead experimental therapeutic, Solanezumab, did not engage with putatively pathogenic Aβ oligomers.
Compelling genetic evidence links the amyloid precursor protein (APP) to Alzheimer's disease (AD). A leading hypothesis proposes that a small amphipathic fragment of APP, the amyloid β-protein (Aβ), self-associates to form soluble assemblies loosely referred to as "oligomers" and that these are primary mediators of synaptic dysfunction. As such, Aβ, and specifically Aβ oligomers, are targets for disease modifying therapies. Currently, the most advanced experimental treatment for AD relies on the use of anti-Aβ antibodies. In this study, we tested the ability of the monomer-preferring antibody, m266 and a novel aggregate-preferring antibody, 1C22, to attenuate spatial reference memory impairments in J20 mice. Chronic treatment with m266 resulted in a~70-fold increase in Aβ detected in the bloodstream, and a~50% increase in water-soluble brain Aβ -and in both cases Aβ was bound to m266. In contrast, 1C22 increased the levels of free Aβ in the bloodstream, and bound to amyloid deposits in J20 brain. However, neither 1C22 nor m266 attenuated the cognitive deficits evident in 12 month old J20 mice. Moreover, both antibodies failed to alter the levels of soluble Aβ oligomers in J20 brain. These results suggest that Aβ oligomers may mediate the behavioral deficits seen in J20 mice and highlight the need for the development of aggregate-preferring antibodies that can reach the brain in sufficient levels to neutralize bioactive Aβ oligomers. Aside from the lack of positive effect of m266 and 1C22 on cognition, a substantial number of deaths occurred in m266-and 1C22-immunized J20 mice. These fatalities were specific to anti-Aβ antibodies and to the J20 mouse line since treatment of wild type or PDAPP mice with these antibodies did not cause any deaths. These and other recent results indicate that J20 mice are particularly susceptible to targeting of the APP/Aβ/tau axis. Notwithstanding the specificity of fatalities for J20 mice, it is worrying that the murine precursor (m266) of a lead experimental therapeutic, Solanezumab, did not engage with putatively pathogenic Aβ oligomers.
© 2015 Elsevier Inc. All rights reserved.
Introduction
Alzheimer's disease (AD) is characterized by amyloid deposition, neurofibrillary tangles, synaptic loss, neuronal loss, reactive gliosis and memory impairment. Several transgenic human amyloid precursor protein (hAPP) mouse models reproduce certain features of AD and have been used to assess the efficacy of therapeutic interventions, including the use of anti-Aβ antibodies. Early studies demonstrated that the anti-Aβ monoclonal antibody (mAb), 3D6 (raised to Aβ 1 − 5 ), reduced cortical Aβ burden by~86% in PDAPP mice (Bard et al., 2000) , whereas when PDAPP mice were treated with the mid-region specific mAb, m266, it had little effect on Aβ deposition but dramatically increased circulating levels of antibody-bound Aβ (DeMattos et al., 2001) . Subsequent studies using other anti-Aβ mAbs and mouse models also demonstrated significant reductions in amyloid burden (Levites et al., 2006; Schroeter et al., 2008) . In addition, several studies found that passive administration of certain anti-Aβ antibodies protected or restored cognition in hAPP mice (Basi et al., 2010; Dodart et al., 2002; Karlnoski et al., 2008; Kotilinek et al., 2002; Oddo et al., 2006; Wilcock et al., 2004a Wilcock et al., ,b, 2006 Zago et al., 2012) . Specifically, m266, was shown to improve object recognition memory in 11 month PDAPP mice 24 h after a single antibody administration (Dodart et al., 2002) . The mechanism of this striking short-term improvement is uncertain, but has been suggested to result due to either: (1) direct neutralization of soluble toxic Neurobiology of Disease 82 (2015) 372-384 
